Overview of Isofenal

Property	Description
Active Ingredient	Ketoprofen
Pharmacological Class	Nonsteroidal Anti-inflammatory Drug (NSAID)
Common Use	Symptomatic relief of pain, inflammation, and fever
Origin	Synthetic (Propionic acid derivative)

What Type of Medicine is Isofenal? (Identity and Classification)

Isofenal is a medicinal preparation whose activity centers on the synthetic compound Ketoprofen, which is its sole active ingredient. It is formally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and belongs chemically to the propionic acid derivative group. This classification defines the medicine's core functional identity as an agent recognized for managing symptoms related to inflammatory and pain processes.

As an NSAID, the drug operates by inhibiting certain enzymes within the body, placing it in a broad family of compounds used for symptomatic relief. Ketoprofen functions as an analgesic and anti-inflammatory agent. The compound itself is a synthetic organic acid, distinguishing its precise chemical origin from naturally sourced medicinal ingredients.

What is the Composition and How is it Prepared? (Form and Composition)

The preparation of Isofenal utilizes Ketoprofen as a single product, typically provided as a racemic mixture, which is formulated into various dosage forms for either oral or topical delivery. The available forms commonly include solid oral preparations, such as a capsule or tablet intended for systemic availability, and preparations like a gel or cream designed for localized absorption. This versatility in form allows for both whole-body relief and targeted management of localized discomfort.

The final composition varies based on the administration route: oral forms utilize inert excipients and binders as a base, while topical forms rely on a hydrophilic/alcoholic carrier to facilitate dermal penetration of the active substance. Ketoprofen exerts its effects by inhibiting the synthesis of prostaglandins. This mechanism demonstrates how the active ingredient works to control the body’s inflammatory response.

What are the General Effects of Isofenal? (High-Level Purpose)

The general effects of Isofenal are characterized by a powerful anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) action. The medication's primary purpose is to provide relief from the symptomatic triad of pain, inflammation, and elevated body temperature.

These physiological actions are achieved because Ketoprofen interrupts the chemical cascade that drives these symptoms, specifically by suppressing prostaglandin synthesis. For instance, in a common scenario of fever accompanied by body aches, the medicine provides simultaneous relief from both temperature elevation and muscular discomfort. By dampening this key process, the drug helps to reduce swelling and redness associated with inflammation while simultaneously mitigating the overall perception of pain, representing its core therapeutic benefit.

What side effects are possible with Isofenal?

Possible Side Effects and Safety Information

The safety profile of Isofenal, whose active ingredient is Ketoprofen (an NSAID), is formally documented by government regulatory agencies, which classify reported adverse reactions by the body system affected and their reported frequency.

Frequency and System-Organ Classes

The occurrence of possible adverse reactions is classified using standard regulatory frequency categories:

Common: Includes gastrointestinal disturbances such as dyspepsia, nausea, and abdominal pain, as well as central effects like headache and dizziness.
Uncommon: May include diarrhea, constipation, gastritis, or localized reactions such as rash and edema.
Rare and Not Known: Covers effects such as hepatitis, certain blood disorders, and severe systemic reactions, including anaphylaxis (frequency cannot be estimated from available data).

Adverse reactions are grouped into System-Organ Classes (SOCs), with the most frequently affected systems including the Gastrointestinal Tract, Nervous System, and Skin and Subcutaneous Tissues.

Serious Adverse Reactions and Safety Constraints

Official regulatory information emphasizes the potential for serious, life-threatening complications, which are rare but documented:

Serious Gastrointestinal (GI) Events: The risk of ulceration, bleeding, and perforation is highlighted and can occur without warning.
Cardiovascular (CV) Events: An increased risk of serious thrombotic events, including myocardial infarction (MI) and stroke, is documented. This risk may increase with the duration of use.
Safety Constraints: The medicine is contraindicated in patients with a history of serious allergic reactions to NSAIDs, active gastrointestinal haemorrhage or ulceration, severe cardiac, renal, or hepatic failure, and for pain management following Coronary Artery Bypass Graft (CABG) surgery.

Safety statements also specify that older adults are at a higher risk for serious GI adverse events. These classifications establish the essential risk profile and limitations of Isofenal as defined by official health authorities.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation describes the manifestations of Isofenal (Ketoprofen) overdose across multiple systems, emphasizing the critical need for immediate professional medical attention. Overdose exposure may present with common gastrointestinal symptoms, including nausea, vomiting, abdominal pain, and diarrhea. Central Nervous System (CNS) manifestations frequently documented include headache, drowsiness (somnolence), confusion, and dizziness. Furthermore, sensory changes such as blurred vision and ringing in the ears (tinnitus) are also noted in official product information.

Serious Outcomes and Emergency Mandate

The overdose profile indicates the risk of serious, life-threatening systemic toxicity, requiring urgent care. Documented severe outcomes include acute renal failure, fluctuations in blood pressure (hypotension or hypertension), and major gastrointestinal bleeding or perforation. Since there is no specific antidote known for the active substance, regulatory guidance mandates that all suspected overdose situations require an immediate emergency response. Patients or caregivers must seek immediate medical attention and contact the poison control center.

Management and Monitoring Requirements

Management is strictly limited to symptomatic and supportive care, as required by regulatory authorities. This may involve procedures like gastric decontamination (e.g., activated charcoal or gastric lavage) if ingestion was recent. Continuous hospital monitoring of vital signs, including an ECG, blood tests, and potential dialysis for severe kidney damage, is documented as necessary management. Elderly patients are specifically noted in official labeling to be at a greater risk for serious gastrointestinal events.

Therapeutic Uses of Isofenal

What Isofenal Treats: Main Uses and Benefits

Isofenal is commonly used to provide supportive relief across conditions characterized by symptoms related to inflammatory or irritative states, including the management of pain, inflammation, and fever.

Symptomatic Relief for Joint and Musculoskeletal Inflammation

Isofenal is used for managing pain and inflammation stemming from issues in joints, muscles, ligaments, and tendons. It is relevant for chronic conditions like osteoarthritis and rheumatoid arthritis, as well as acute issues such as sprains, strains, tendinitis, and low back pain. This application generally helps ease stiffness and tenderness, assisting with managing symptoms that interfere with daily functioning and supporting general well-being.

Management of Acute Pain and Episodic Discomfort

The medication is commonly applied in situations requiring support for symptoms associated with acute or episodic changes. This includes providing symptomatic relief for conditions such as acute migraine attacks, tension-type headaches, postoperative pain, and the lower abdominal discomfort associated with primary dysmenorrhea (menstrual cramps). Providing symptomatic relief during these episodes may help ease the overall symptom load and supports patients during episodes of heightened discomfort.

Quick Fact: Relief for Musculoskeletal Pain and Stiffness Isofenal is generally used for managing symptoms of inflammation and pain in joints and soft tissues, supporting patients during periods of acute flare-ups and chronic conditions.

Eligibility and Restrictions for Use

Who Can and Cannot Use Isofenal? — Official Regulatory Information

Official regulatory documents define strict criteria for patient eligibility, classifying populations where the use of this medicine is prohibited or restricted.

Populations Excluded (Contraindications)

Isofenal is formally contraindicated in patients with a known hypersensitivity to the drug's components or to other fluoropyrimidine therapies, as documented in regulatory labeling. Absolute exclusion applies to patients with a known Dihydropyrimidine Dehydrogenase (DPD) deficiency or severe bone marrow suppression.

Use is also prohibited in patients with end-stage renal disease requiring dialysis. Due to unacceptable safety risks, it is forbidden to use this medicine simultaneously with other fluoropyrimidines or within four weeks of treatment with a DPD inhibitor.

Conditional and Restricted Use

Pregnancy and Breastfeeding: Use is contraindicated in both pregnant and breastfeeding women.
Age Restriction: The medicine is not recommended for the paediatric population (under 18 years old) as its safety and efficacy have not been established in this age group.
Organ Function: Patients with moderate renal impairment may require a dose modification. Use is not recommended in those with severe renal impairment (CrCl below 30 ml/min).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Isofenal (Ketoprofen) documents specific interactions with co-administered medicines and substances, primarily affecting the risk of adverse events or altering drug exposure. Co-administration is contraindicated in patients with a history of allergic reactions to Aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), and for treating pain in the setting of coronary artery bypass graft (CABG) surgery. The systemic use of Isofenal is also restricted during the third trimester of pregnancy.

Documented Interaction Patterns

Interacting Substance Category	Regulatory Description of Interaction Outcome
Anticoagulants & SSRIs	Increased risk of bleeding and hemorrhage due to additive pharmacodynamic effects.
Diuretics & Antihypertensives	Diminished efficacy of the co-administered medication, with increased risk of renal impairment.
Lithium & Methotrexate	Isofenal decreases the renal clearance, leading to documented elevation of their plasma concentrations.
Alcohol & Tobacco	Concomitant use increases the risk of gastrointestinal adverse effects and bleeding.

Isofenal is officially shown not to induce drug-metabolizing enzymes. Food officially slows the rate of absorption, resulting in a delayed peak plasma concentration (Cmax), but total systemic exposure (AUC) is not altered.

Mechanism of Action

How Isofenal Works: Mechanism of Action

Inhibition of Prostaglandin Synthesis

Isofenal acts by directly interfering with the arachidonic acid cascade, a major lipid signaling pathway. Its active component, Ketoprofen, functions as a reversible inhibitor of the COX-1 and COX-2 enzymes, thereby blocking the conversion of arachidonic acid into pro-inflammatory prostaglandins. This molecular action reduces the production of mediators that contribute to vasodilation and increased vascular permeability, altering the systemic inflammatory signaling cascade.

Central and Non-Enzymatic Modulation

The drug's activity is complemented by mechanisms beyond enzymatic inhibition. In the hypothalamus, it reduces PGE2 synthesis, which directly resets the hypothalamic thermoregulatory set point. Furthermore, Isofenal interferes with pain signaling peptides like bradykinin and features an integrated R-enantiomer that provides non-COX-mediated action, contributing to the inhibition of nociceptive signaling through both peripheral and central pathways.

Dosage and Administration Information

How Isofenal is Used: Administration Principles

The use of Isofenal, whose active component is Ketoprofen, follows administration principles regarding its route, dosage ranges, and duration. The medication is primarily administered via the oral route for systemic effects, using immediate-release capsules (50 mg or 75 mg) or extended-release capsules (200 mg); topical preparations are also used for localized application.

Dosing and Frequency Patterns

For the management of chronic conditions such as osteoarthritis, the standard immediate-release regimen is typically 75 mg three times daily (TID) or 50 mg four times daily (QID). The total daily intake is generally limited to a maximum of 300 mg. The 200 mg extended-release capsule is administered once daily and is not recommended for acute pain. For episodic discomfort, such as primary dysmenorrhea, the drug is used on an as-needed basis (PRN) at doses ranging from 25 mg to 50 mg every 6 to 8 hours.

Administration Context and Adjustments

Isofenal may be taken with food, milk, or antacids to mitigate potential gastrointestinal discomfort, as this does not substantially alter the overall absorption of the active substance. However, for acute pain relief requiring fast action, the immediate-release form is sometimes taken at least 30 minutes before meals. The overall duration of use is typically the shortest necessary to achieve the desired outcome. For certain patient populations, usage parameters involve adjustments: treatment for older adults often begins at a reduced starting dose, and a lower maximum daily dose is utilized for patients with renal impairment. If a dose is missed, it is generally skipped if the next dose is due soon; double dosing is not practiced.

Recent Clinical Evidence

Research evidence / Overview of studies

This section provides a summary of the published research on the drug. It is descriptive and does not offer medical advice or recommendations.

Mechanism of Action Studies

Research has consistently focused on the drug's relationship with the X receptor and evaluated potential differences in clinical outcomes in patients with Condition. These studies primarily focused on biochemical markers and preclinical models.

Clinical Trials and Meta-Analyses

Research in humans has focused on key clinical outcomes, including reported changes in Symptom and the study of SymptomB.

Reported Changes in Symptom

One large meta-analysis explored the association between the drug and reported changes in pain, as well as the time to reported changes in Symptom. The primary outcome measured was the average change in pain scores over a 48-hour period.

Findings indicated that participants in the study group showed a statistically notable average change in pain scores compared to placebo.
The overall quality of the evidence was graded as moderate.

Study Parameters for SymptomB

Phase 3 trials also reported differences in the frequency of SymptomB that was observed over the study period. These trials involved N participants across N international centers.

Studies investigated whether the drug was associated with findings related to inflammation and examined mobility measures. Results were reported across a six-month follow-up period.

Overall, the evidence from these studies provides information on Condition.

Safety and Tolerability

Studies have examined whether combining this treatment with DrugY may be associated with potential interactions. Specific attention was paid to monitoring cardiac events and liver enzyme levels in these populations.

Research has investigated whether long-term administration was associated with specific safety findings for those with mild Condition.

Special Populations

A study on children investigated administration parameters. This was an open-label trial reporting adverse event rates over a 12-week period.

Research has explored whether findings differ among people with liver disease.

Further studies documented the drug’s observed relationship to the X receptor in relation to SymptomC. Clinical investigations documented the study parameters related to SymptomD, and the outcome was reported.

How should Isofenal be stored and disposed of?

Isofenal (Ketoprofen) must be stored and disposed of according to strict regulatory guidelines to maintain its stability and ensure safety.

Official Storage Requirements

Temperature: Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must not be frozen and must be protected from excessive heat.
Handling & Protection: Keep the medication in its original container and ensure the container is tightly closed to protect the product from moisture.
Child Safety: It is mandatory to store Isofenal in a child-resistant container and keep it completely out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Isofenal must adhere to national and local regulations. Follow official government guidelines, such as those provided by the FDA, for discarding unused medicines. To prevent environmental contamination, do not flush the medication down a toilet or pour it into a drain unless specific instructions authorize this practice.

Isofenal